

Transparency in our dealings with the Healthcare and Patient Communities

GW is passionate about advancing medicines in the fields of cannabinoid science and developing therapies to address serious medical needs with limited treatment options, particularly in neurological conditions. Healthcare professionals, healthcare organisations and the patient community all have an important role to play in this work. There is much that we can learn from them about the conditions they treat or live with as well as the everyday practical use of our medicines. This collaboration is essential to drive innovation in the development of medicines and to deliver the best treatment options for patients.

We also recognise that it is crucial that patients and the public have faith in our industry and the important work we are carrying out to advance research and treatment in areas of high unmet need. That is why we are committed to transparency in our financial dealings with the healthcare and patient communities.

To the extent we are permitted by law, we disclose our payments to healthcare professionals and healthcare organisations in the United Kingdom on the ABPI Disclosure platform annually on or around 30th of June covering the previous calendar year. Payments in France are published on the DGS (Department of the Ministry of Health) National Public Platform by 1st September of each year for the benefits granted during the first half of the year and by 1st March of each year for the benefits granted during the second half of the preceding year. All other payments to HCPs in other countries outside of the United States are uploaded to our websites.

Patient Organisation Support

GW was founded to respond to the needs of patients. As a result, we understand the importance of partnering with Patient Organisations, patients and carers in order to deliver better medicines and better outcomes for patients. GW has a legitimate interest in supporting initiatives and organisations related to the advancement of research, disease awareness, education, and patient programs. GW also relies upon the expert knowledge provided by patient organisations. As such, the principle purpose of exchange with Patient Organisations is to enhance patient care, improve the lives of patients and improve the health of communities which we serve. Increasing transparent engagements with Patient Organisations has led to better trials, better engagements and greater communication throughout the life cycle of medicines. This has resulted in better patient outcomes.

GW is committed to disclosing transparently all financial support and significant non-financial support given to Patient Organisations. Below are the details of patient organisations we have supported across Europe.

2021

Patient Organisation	Finance (Local Currency)	Local Currency	Description
GW UK			
Young Epilepsy	30,000 GBP		A clinical and neurodevelopment follow-up of EpiPEG participants. Assessing the progress of children who had epilepsy

			during the first year of life as they turn 6yrs old.
	12,000 GBP		Sponsorship of Young Epilepsy Virtual Research Retreat.
Reverse Rett	10,000 AUD		The World Rett Syndrome Congress being held in Australia.
Tuberous Sclerosis Association	10,000 GBP		Providing support to individuals living with TSC and their families during pandemic.
	577.50 GBP		Advice and consultancy services provided for TSC Patient Organisation Advisory Board.
	20,000 GBP		Symposium sponsorship for 2021 International Tuberous Sclerosis Complex Conference
Samson Centre for MS	300 GBP		To provide Consulting services to provide expert advice on spasticity.
British Epilepsy Association	2,000 GBP		IBE's 50 million Steps for Epilepsy campaign
International Brain Tumour Alliance IBTA	2,000 GBP		General support for the IBTA's New projects 2021.
Dravet Syndrome UK	40,000 GBP		To sponsor DSUK Conference 2021
Epilepsy Society	30,660 GBP		Providing Epilepsy Awareness & Seizure First Aid training during March and April 2021.
Sibs	2,300 GBP		Project to support research, drafting, liaising, editing website to support siblings following a diagnosis of their brother or sister. To provide support and answer questions.
The Multiple Sclerosis Trust	20,000 GBP		To provide support for people with MS in communities most

			impacted by funding shortages.
Multiple Sclerosis Trust Education	2,520 GBP		Sponsorship for MS Trust Virtual Conference 28th February - 2nd March 2021
Matthew's Friends	9,000 GBP		Sponsorship 7th Global Symposium for Ketogenic Dietary Therapies.
GW Spain			
Asociacion de Voluntarios en Favor del Sindrome de Dravet	6,050 EUR		Sponsorship for the III international Congress on Dravet Syndrome and Refractory Epilepsy June 17-20 2021 Virtual www.epibilbao.com
Dravet Syndrome Foundation Delegacion En Espana	5,000 EUR		Sponsorship of Fundación Síndrome Dravet Summer Course virtually from the 7th to the 9th July 2021.
	11,358.10 EUR		Sponsorship of Fundación Síndrome Dravet. Telemedicine for the management of DS Patients.
	5,000 EUR		DS Foundation 2021/2022 activities
Federacion Espanola de Enfermedades Raras	6,050 EUR		Patrocinio Carrera FEDER por la Esperanza 2021
	6,050 EUR		Patrocinio Carrera FEDER por la Esperanza 2022
Asociacion Española de Esclerosis Tuberosa	437.50 EUR		Consultancy services
Federacion Espanola De Epilepsia	2,000 EUR		Support for the 3rd Research Fair in Epilepsy
	1,000 EUR		Donation
GW Italy			
Dravet Italia Onlus	25,000 EUR		Project support incorporating: Dialog EpiCare & Association,

			Annual meeting, platform webinar.
Federazione Italiana Epilessie	1,000 EUR		charitable contribution to the IBE chapter 50m steps.
SCN8A ITALIA ODV	6,000 EUR		Support for disease awareness training for patients and families on SCN8A-related epilepsy.
Associazione Sclerosi Tuberosa	10,000 EUR		Grant for Medical Education
Croatia			
Dravet Syndrome Croatia	5,000 EUR		Support for Project EpiPrehrana which is in collaboration with 'Matthews Friends' to raise awareness and educate about diet and therapeutic effects for patients with refractory epilepsy

Payments Include VAT where applicable